The EANO website serves the neurooncology community by providing current research news on neurooncology topics, facilitating collaboration on research projects, advertising job opportunities, providing a discussion forum for members and disseminating information about relevant events.
EANO members can login to access the full website. If you're not a member, find out here how to become an EANO member.
Invitation for the General Assembly of EANO
Dear Friends,
You are invited to participate in the General Assembly of EANO on September 18.
Bevacizumab therapy for radiation necrosis of the CNS
The development of effective therapy for CNS radiation necrosis is complicated because the mechanisms of radiation-induced injury are not completely understood. Current opinion is that radiation necrosis is a continuous process from endothelial cell dysfunction to tissue hypoxia and necrosis, with ...
Commentary on the study ‘Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab for Radiation Necrosis of the Central Nervous System’*
By Dr. Damien Ricard, Service de Neurologie,
Hôpital d’Instruction des Armées du Val-de-Grâce, Paris, France.
Focal cerebral and spinal cord radionecrosis, which primarily affects the white matter, is a severe radiation-induced complication which is neuropathologically defined as necrosis with severe vascular lesions (stenosis, thrombosis, haemorrhage, fibrinoid vascular necrosis). Radionecrosis usually develops in the first 2 years after standard conventional RT (for intracranial tumours or head and neck tumours with irradiation fields including temporal lobes of the brain), but can appear decades after treatment.
Mini Symposium on Neuro-Oncology in Eastern European and Northern African Countries
During the EANO Meeting in Maastricht, on September 19, a multidisciplinary Symposium on "Neuro-Oncology in Eastern European and North African Countries" will take place.
The objective is to compare the organization of Neuro-Oncology in Western and non Western countries and establish future forms of cooperation. Speakers from different countries and different professional will give an overview of the status of Neuro-Oncology in their respective countries.
EANO Executive Board Renovation
The EANO Board will be renovated after our Congress in Maastricht, September 2010. The present Board wants the election process be open to all member’s participation. To be in the EANO Board requires that all candidates are willing to dedicate part of their busy schedule to the expansion of our society. All applicants must be members of EANO (i.e. paid-up members).
At present time we have 3 posts open for nominations:
The mechanics of the nomination is that: 
From our Swish Correspondent, Dr. Andreas F. Hottinger
Switzerland lies in the middle of Europe. Despite this (or because of this), we Swiss people have a tendency to do things very differently than the rest of Europe. Since last year, and thanks to (or because of) bevacizumab, this adage also applies in neurooncology. Bevacizumab is a monoclonal antibody against vascular endothelial growth factor.
|